United Therapeutics Co. (NASDAQ:UTHR) Stock Holdings Reduced by Polaris Capital Management LLC

Polaris Capital Management LLC decreased its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 7.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 131,850 shares of the biotechnology company's stock after selling 10,100 shares during the quarter. United Therapeutics accounts for approximately 2.2% of Polaris Capital Management LLC's holdings, making the stock its 9th largest position. Polaris Capital Management LLC owned 0.30% of United Therapeutics worth $46,522,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC boosted its position in United Therapeutics by 0.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company's stock valued at $1,761,000 after purchasing an additional 39 shares during the period. MBM Wealth Consultants LLC boosted its position in United Therapeutics by 1.9% during the 4th quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company's stock valued at $775,000 after purchasing an additional 41 shares during the period. First Citizens Bank & Trust Co. boosted its position in United Therapeutics by 1.8% during the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company's stock valued at $961,000 after purchasing an additional 48 shares during the period. Signaturefd LLC boosted its position in United Therapeutics by 8.8% during the 3rd quarter. Signaturefd LLC now owns 633 shares of the biotechnology company's stock valued at $227,000 after purchasing an additional 51 shares during the period. Finally, UMB Bank n.a. boosted its position in United Therapeutics by 4.9% during the 4th quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company's stock valued at $388,000 after purchasing an additional 51 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. LADENBURG THALM/SH SH boosted their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. HC Wainwright boosted their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. The Goldman Sachs Group boosted their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. Finally, StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $382.08.

Insider Transactions at United Therapeutics

In related news, Director Nilda Mesa sold 255 shares of the company's stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now directly owns 5,528 shares of the company's stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the company's stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at $13,485,785.60. The trade was a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 121,864 shares of company stock valued at $44,516,965 over the last three months. Company insiders own 11.90% of the company's stock.

United Therapeutics Trading Down 0.6 %

Shares of United Therapeutics stock traded down $2.16 on Friday, reaching $368.28. 106,552 shares of the company were exchanged, compared to its average volume of 321,900. The stock has a fifty day moving average price of $361.91 and a 200-day moving average price of $358.41. The firm has a market capitalization of $16.44 billion, a price-to-earnings ratio of 16.20, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. United Therapeutics Co. has a fifty-two week low of $211.61 and a fifty-two week high of $417.82.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.